The term of metabolic syndrome is used to describe a combinationof metabolic disorders that all together, increase the risk oftype 2 diabetes mellitus (T2DM) and cardiovascular diseases.The components of metabolic syndrome are including the presenceof central obesity, dyslipidemia, glucose intolerance and hypertension The worldwide prevalence of metabolic syndrome isvariable, ranging from 10% to 84%, depending on geographical originsand composition of the studied population Metabolicsyndrome prevalence has been increased substantially in the lasttwo decades which should be a priority for public health It isestimated that people with metabolic syndrome are twice as likelyto die and three times as likely to have a heart attack or strokecompared with people without the syndrome Moreover,compared with persons without metabolic syndrome, those withthe syndrome have an approximately 5-fold increase in diabetesrisk. However, when metabolic syndrome combines with prediabetes,the risk is increased even more Indeed, two clinicalconstructs for identifying individuals at high risk of developingtype 2 diabetes are metabolic syndrome and prediabetes.
Thus,effective treatment of these at-risk individuals is imperative for theprevention of type 2 diabetes To date, the intestinal microbiota has been interested in itsequivocal impact on health and is an emerging investigative field The connection between metabolic syndrome and gut microbiotais now acknowledged and some of the therapeutic strategieshave been proposed to improve the composition of the gutmicroflora in order to promote optimal metabolic health Current investigations suggest that manipulation of the gutmicrobiota by probiotics, prebiotics, and synbiotics could be apromising approach for the management of metabolic syndrome
